Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.
about
Midkine and the kidney: health and diseasesMidkine in nephrogenesis, hypertension and kidney diseasesMidkine inhibitors: application of a simple assay procedure to screening of inhibitory compoundsMidkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice.Neuroglycan C is a novel midkine receptor involved in process elongation of oligodendroglial precursor-like cells.Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.Midkine: a promising molecule for drug development to treat diseases of the central nervous systemMidkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.Midkine in the pathology of cancer, neural disease, and inflammation.The heparin-binding growth factor midkine: the biological activities and candidate receptors.Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription.Efficacy of urinary midkine as a biomarker in patients with acute kidney injury.Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model.Erythropoietin reduces lipopolysaccharide-induced cell Damage and midkine secretion in U937 human histiocytic lymphoma cells.(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity.Restoring the renal microvasculature to treat chronic kidney disease.Midkine in inflammation.Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges
P2860
Q27005733-4DC17F8F-DE60-43D8-A77F-C9A9FEF36541Q27006801-24EE1955-C26A-47B5-869F-56B0E3EE99B7Q33968267-2112921A-14D0-4715-8784-A610783601E1Q34506576-B0764439-BA27-4A59-A3E3-DEE8728B47E6Q34556247-82356129-A63C-44E6-A083-2202AB293F8FQ35070717-18360AE4-F232-47BE-87DE-8795BFEBA1AFQ35402367-13051200-1D92-43D7-B5EA-14C8781811DBQ35701268-45A1EC3D-C9A8-4B2A-B45B-67069111901AQ36160231-92C85672-18F4-4F9C-A80E-198550EC7E9CQ38020971-6491AA1F-B72C-4C17-996E-0CE83D893246Q38102670-8301ED42-D7C9-48FF-87FD-8E331D9CEBD3Q38181600-1C103568-81C4-4498-80E2-92581273F8F3Q38332355-4FDC534E-C97E-4345-82AB-861401E6DD49Q39207404-102BDB4F-DFA6-491D-BB7E-04FD5302A62FQ39921082-8225B386-22E1-4C3D-8916-AD959999C9B5Q40619565-453BA027-1B71-4544-8731-A36ACA51E9AAQ44364802-E1BCCDD3-BBC9-4070-A1F6-78FD0C1E1ADAQ46606027-CD793F57-3CA4-4E8E-BE15-DCCFBE5B91F2Q47706038-BD14DA29-5940-49BE-B969-ADCDE6F6A77BQ51632066-B09CFF7D-D182-40AB-A8A8-4B61A318E127Q55648295-C697647C-EA0D-4F8F-B2D6-42FB0936E27DQ57112108-300C6AF4-CC0F-472D-94B5-E8585691BB4D
P2860
Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Lack of the growth factor midk ...... isplatin-induced renal damage.
@en
type
label
Lack of the growth factor midk ...... isplatin-induced renal damage.
@en
prefLabel
Lack of the growth factor midk ...... isplatin-induced renal damage.
@en
P2093
P2860
P1476
Lack of the growth factor midk ...... isplatin-induced renal damage.
@en
P2093
Hanayo Kawai
Kenji Kadomatsu
Seiichi Matsuo
Takashi Muramatsu
Tomoki Kosugi
Waichi Sato
Yoshifumi Takei
Yukio Yuzawa
P2860
P304
P356
10.1016/S0002-9440(10)63417-7
P407
P577
2004-11-01T00:00:00Z